Diseases & Research

Cervical Cancer

cervical cancer cells

Invasive squamous cell cancer

Fred Hutchinson Cancer Research Center

Click for high-res version

Hutchinson Center researchers played an integral role in developing lifesaving vaccines for the human papillomavirus (HPV), which causes cervical cancer, and continue making breakthrough discoveries about the disease.

Click the tabs below to learn more about our research »

Fast Facts

  • Cervical cancer develops in the tissues of the cervix, which connects a woman’s uterus and vagina.

  • Cervical cancer is usually a slow-growing cancer that may not have symptoms but can be found with regular Pap tests, a procedure in which cells are scraped from the cervix and scrutinized under a microscope.

  • Human papillomavirus (HPV), a sexually transmitted disease, is cervical cancer's primary cause.

  • There are now two vaccines, approved for males and females ages 9 to 26, that protect against the types of HPV that cause most cervical cancer cases.

  • Since most women are exposed to the kind of HPV that cause cervical cancer but do not develop cancer, it is likely that other factors contribute to the diseases's development of cervical cancer. Some of these factors include early age at first intercourse, cigarette smoking, nutrition and genetics.

  • Cervical cancer used to be one of the most common causes of cancer death among American women, but thanks to widespread use of the Pap test, early detection has significantly improved and boosted U.S. survival rates. However, cervical cancer remains one of the leading causes of cancer death among women in low-resource countries.

[back to top]

Prevention & Causes

Hutchinson Center researchers played a pivotal role in developing vaccines that prevent infections that cause cervical cancer, and are pursuing more innovative treatments:

Developing the HPV Vaccine - Dr. Denise Galloway and colleagues made discoveries that led to Gardasil and Cervarix, the two vaccines that have been found to prevent HPV infection in women. Gardasil, approved for use in the U.S. in 2006, prevents the types of HPV that account for 70 percent of cervical cancers and 90 percent of genital warts. Cervarix is licensed for use in Europe. Learn more »

New research shows that the HPV vaccine may do more than just prevent cervical cancer. Because HPV is now linked to anal, vaginal, vulvar and penile cancers, as well as cancer of the oropharynx (the middle part of the throat including the soft palate, the base of the tongue, and the tonsils), the vaccine is even more effective in preventing cancer than first thought.

Unraveling genes' role in cervical cancer – Research by Dr. Margaret Madeleine and colleagues found that certain gene variants may lead to cervical cancer in women infected with HPV. By analyzing immune-system genes of women with and without cervical cancer, researchers found evidence that certain gene variants may affect women's cancer risk. The discovery may help explain why only a small proportion of women infected with HPV's cancer-causing form aquire the disease, and may accelerate the pursuit of new treatments. Learn more »

[back to top]

Detection & Diagnosis

Increasing screening in ethnic communities – Hispanic women have about twice the risk of developing invasive cervical cancer as non-Hispanic women, and Hispanic women are less likely to get regular Pap tests. Research by Dr. Carol Moinpour and colleagues has suggested that training Hispanic female cancer survivors as health educators can successfully increase cancer-screening rates among their network of family members and friends. Learn more »

Vietnamese women have higher rates of cervical cancer than any other racial or ethnic group (including Hispanics), according to cancer-registry data. Surveys of Seattle-area Vietnamese-American women led by Drs. Vicky Taylor, Stephen Schwartz and colleagues have shed some light on the cultural beliefs that may explain why such women tend not to be screened regularly. Learn more »

[back to top]

Treatment & Prognosis

Predicting mortality – Dr. Stephen Schwartz and colleagues observed that a strain of human papillomavirus called HPV 18, found in up to 30 percent of women with cervical cancer, appears to be associated with a mortality rate nearly double that of other HPV-related cervical cancers. The research's results confirm several previous smaller studies that suggest HPV 18 may be an excellent indicator, or biomarker, for predicting outcomes for women diagnosed with early-stage cervical cancer. Learn more »

[back to top]

Seattle Cancer Care Alliance logo

Fred Hutch's clinical research breakthroughs are delivered to patients through our treatment arm, the SCCA.

Make an appointment
Healthy volunteers

Healthy volunteers are critical to prevention and early detection research.

Find a Study
Clinical trials unit patient lounge

Clinical trials are vital to the development of innovative treatments for Cervical Cancer.

Find a Clinical Trial
Researcher in lab

Fred Hutch scientists are producing some of the most important breakthroughs in the prevention, early detection and treatment of cancer, HIV and other diseases.

Donate to our Research
Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.